Skip to main content
Clinical Trials/NCT07646470
NCT07646470CompletedNot Applicable

Effects of Non-Invasive Vagus Nerve Stimulation on Rheumatoid Arthritis: A Longitudinal Prospective Case Study.

Osteoflow Health Clinic1 site in 1 country1 target enrollmentStarted: January 30, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
1
Locations
1

Study Overview

Brief Summary

The goal of this clinical trial is to learn if chronic self-administrated non-invasive vagus nerve stimulation works to improves the disease activity in a single asplenic patient suffering from rheumatoid arthritis. It will also learn about the safety of at-home chronic non-invasive vagus nerve stimulation. The main questions it aims to answer are:

Does chronic non-invasive vagus nerve stimulation improves the disease activity? Does chronic non-invasive vagus nerve stimulation decrease CRP serum level? Does chronic non-invasive vagus nerve stimulation improve HRV and the sympathy-vagal balance?

Participant will:

Stimulate at home the left auricular branch of the vagus nerve for 24 months with three different protocol of stimulation (parameters and duration) Visit the clinic once every 2 months for checkups and tests Will have blood work for CRP level check every 8 months

Detailed Description

The study used a repeated measures design. After instructions on the use of a standard nVNS device, the patient was given an "at-home" nVNS-treatment protocol for 24-month run-in period, that was divided in three 8-month treatment blocks where each block-period consisted of active nVNS with specific settings and daily stimulation time. Each block was divided in 4-time assessment i.e., AAAA-BBBB-CCCC, once every 2 months. No washout period was included.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • diagnosed RA
  • splenectomy

Exclusion Criteria

  • Pharmaceutical treatment as:
  • disease-modifying antirheumatic drugs (DMARDs)
  • Biologics
  • Jak inhibitors

Investigators

Sponsor
Osteoflow Health Clinic
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pascal JD Grolaux

Principal Investigator

Universidad Francisco de Vitoria

Study Sites (1)

Loading locations...

Similar Trials